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ARTICLE
SPT6-driven error-free DNA repair safeguards
genomic stability of glioblastoma cancer stem-like
cells
Elisabeth Anne Adanma Obara1,10, Diana Aguilar-Morante 1,10, Rikke Darling Rasmussen1,10, Alex Frias1,
Kristoffer Vitting-Serup1,2,3, Yi Chieh Lim 1, Kirstine Juul Elbæk1, Henriette Pedersen1, Lina Vardouli1,
Kamilla Ellermann Jensen1, Jane Skjoth-Rasmussen4, Jannick Brennum4, Lucie Tuckova5,6, Robert Strauss 7,
Christoffel Dinant7, Jiri Bartek7,8 & Petra Hamerlik 1,9✉
Glioblastoma cancer-stem like cells (GSCs) display marked resistance to ionizing radiation
(IR), a standard of care for glioblastoma patients. Mechanisms underpinning radio-resistance
of GSCs remain largely unknown. Chromatin state and the accessibility of DNA lesions to
DNA repair machineries are crucial for the maintenance of genomic stability. Understanding
the functional impact of chromatin remodeling on DNA repair in GSCs may lay the foundation
for advancing the efficacy of radio-sensitizing therapies. Here, we present the results of a
high-content siRNA microscopy screen, revealing the transcriptional elongation factor SPT6
to be critical for the genomic stability and self-renewal of GSCs. Mechanistically, SPT6
transcriptionally up-regulates BRCA1 and thereby drives an error-free DNA repair in GSCs.
SPT6 loss impairs the self-renewal, genomic stability and tumor initiating capacity of GSCs.
Collectively, our results provide mechanistic insights into how SPT6 regulates DNA repair
and identify SPT6 as a putative therapeutic target in glioblastoma.
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The integrity of mammalian genomes is continuously chal-lenged by DNA double-strand breaks (DSBs), cytotoxiclesions that can be generated by cell-intrinsic processes,
including DNA replication, transcription, and metabolism,
resulting in an oxidative and replication stress. Thus, a functional
DNA damage response (DDR) promoting DNA repair and cell
cycle checkpoints is crucial for cellular survival1. The DDR
encompasses a network of proteins that sense and respond to
DSB formation. The failure or error-prone repair of DSBs can
lead to cell death or accumulation of deleterious gross chromo-
somal aberrations, such as deletions, translocations, and fusions
that promote genomic instability and tumorigenesis2. Rampant
genomic instability and marked resistance to DNA damaging
therapies are among the hallmarks of glioblastoma (GBM), one of
the deadliest of solid tumors with median survival rates of
~15 months3. The causes of therapeutic resistance are diverse, but
hierarchical organization of this disease with therapeutically
resistant cancer stem-like cells (CSCs) at the apex is assumed a
plausible cause of treatment failure ultimately leading to tumor
recurrence4. Previously, we and others have demonstrated that
gliomas, in general, and GBM-derived cancer stem-like cells
(GSCs), in particular, display constitutive DDR activation as a
consequence of continuous exposure to replication and oxidative
stress5–11.
Eukaryotic cells have developed two major mechanisms for
DSB repair: error-free homologous recombination (HR) and
error-prone non-homologous end-joining (NHEJ)12. The choice
of DSB repair is dictated by the antagonistic relationship of p53-
binding protein 1 (53BP1) and breast cancer susceptibility protein
type 1 (BRCA1) in the context of cell cycle stages. BRCA1 pro-
motes HR by activating end-resection, which occurs in the S and
G2 phases of the cell cycle, when sister chromatids are available.
NHEJ prevails in G1 and is controlled by 53BP1, which acts as a
barrier to HR by inhibiting DNA-end resection. Consequently,
cells lacking BRCA1 display aberrant activation of NHEJ at
replication-associated DSBs in S/G2 cell cycle phase, leading to
gross chromosomal rearrangements13–15. Mouse studies have
shown that 53BP1 loss causes growth retardation, immunodefi-
ciency and radio-sensitivity, while preventing the chromosomal
aberrations seen in BRCA1 null animals, stressing the importance
of BRCA1-dependent removal of 53BP1 to mediate the transition
from NHEJ to HR14,16,17.
Accumulating evidence suggests a crucial role of the chromatin
state in DNA replication, transcription, repair and genomic sta-
bility of human cells. Chromatin compaction represents a major
constraint limiting the timely access of DNA repair factors, which
is crucial for efficient recognition and removal of DNA lesions18.
Previously, we reported that BRCA1, a TF and chromatin
remodeler, mediates responses of GBM cells to supra-
physiological replications stress9, an inherent feature of this
deadly disease6. Supporting the clinical relevance of chromatin
regulation, several chromatin remodeling factors were identified
as essential for GSC maintenance, thus opening a novel avenue
for therapeutic intervention in GBM19,20.
Based on this background, we hypothesized that GSCs and the
differentiated GBM cells (DGCs) differ in their dependency on
chromatin remodeling genes to enable efficient DNA repair,
which confers the superior capacity of GSCs to evade DNA
damaging therapies. Using matched patient-derived GSCs and
DGCs, we carried out a high-content siRNA screen, which
identified the histone chaperone and transcription elongation
factor SPT6 (Suppressor of Ty 6 homolog) as a key regulator of
error-free DNA repair in GSCs. Moreover, SPT6 drives a stem
cell transcriptional program to promote GSC maintenance and
tumorigenicity in vivo, thus supporting SPT6 as a novel ther-
apeutic target in GBM.
Results
siRNA screen identifies a role for SPT6 in DNA repair of GSC.
DNA damage poses a serious threat to cell survival by compro-
mising both genomic and epigenomic integrity. DDR activation is
accompanied by chromatin remodeling, affecting intrinsic chro-
matin components and epigenetic marks, thereby assuring the
accessibility of DNA lesions and timely recruitment of DNA
repair machinery21. At baseline, the GSCs accumulate a sig-
nificantly lower amount of DSBs (Fig. 1a) compared to DGCs.
This observation together with previously reported dependency of
GSCs on chromatin remodeling factors19,22 prompted us to
interrogate the impact of the chromatin state on DNA repair
efficiency of matched GSC and DGC sub-populations. We per-
formed a microscopy-based screen using a siRNA library cover-
ing 296 chromatin remodeling genes. Candidates were selected
whose knockdown augmented DSBs, which we assessed by
scoring γH2AX mean intensity (MI) (Fig. 1b and Supplementary
Data 1). Z-score was calculated for γH2AX MI in matched
patient-derived GSCs and DGCs (Supplementary Data 2 and
Fig. 1c) and candidates were selected that induced γH2AX MI
(≥20% fold change over the mean of scrambled controls) in GSCs
but not in DGCs. Factors such as WEE1, CHK1, and BRCA1,
with an already established role in DNA repair, ranked among the
top hits. The largest induction of γH2AX MI was seen upon
downregulation of the Suppressor of Ty 6 homolog (SPT6), a
histone chaperon that binds the C-terminal repeat domain (CTD)
of RNAP II via its tandem SH2 domain23–26, and is essential for
transcription elongation of RNAP II-transcribed genes27. Further
validation experiments using a pool of three independent siRNAs
targeting SPT6 (siSPT6-p) as well as individual siRNAs (siSPT6-
34; siSPT6-35; siSPT6-36) confirmed that SPT6 loss-mediated
DSBs induction is unique to GSCs (assessed by γH2AX MI,
γH2AX foci count quantification or immunoblot; Fig. 1d–f;
Supplementary Fig. 1).
SPT6 is essential for GSC maintenance. Based on the selective
induction of DSBs upon SPT6 silencing in GSCs, we measured
the relative expression of SPT6 in three matched pairs of GSCs
and DGCs. On immunoblot, GSCs preferentially expressed SPT6
protein relative to DGCs (Fig. 2a). The difference in SPT6 protein
levels translated to a higher dependency of GSCs on SPT6
expression in vitro, as its silencing reduced the viability of GSCs
to a greater extent than that of DGCs, impaired their self-renewal
as well as differentiation potential (Fig. 2b–e and Supplementary
Fig. 2a–b). One of the key properties of GSCs is the capacity to
initiate tumors in immunocompromised hosts. GSCs transduced
with either shRNA targeting luciferase (shLuc) or two indepen-
dent shRNAs targeting SPT6 (shSPT6-1 and shSPT6-2) were
implanted orthotopically into immunocompromised mice. SPT6
loss extended the median survival of tumor-bearing mice from 29
(shLuc) to 43.5 days for shSPT6-2 (p= 0.0041). The median
survival for shSPT6-1 group was not reached as four animals
remained alive at the end of study (Fig. 2f, g; for the impact of
shRNA-mediated knockdown using shSPT6-1 and shSPT6-2 on
the viability of GSCs in vitro, see Supplementary Fig. 2c–d).
Altogether, these findings validate SPT6 as a regulator of CSCs’
maintenance.
To determine the molecular mediators of SPT6 function in
GSCs, we performed differential RNA analysis (further referred to
as the SPT6 data set) analysis of GSCs transfected with control
siRNA (siCON) or siRNA targeting SPT6 (siSPT6-p) (Supple-
mentary Data 3). Supportive of the inherent dependency of GSCs
on SPT6 expression, gene set enrichment analysis revealed
significant downregulation of gene sets involved in stem cell
maintenance and differentiation (Supplementary Fig. 2e,
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Supplementary Data 4). To further validate our findings, we
leveraged the Suva data set covering differential expression
profiles of three matched GSCs and DGCs28. A Spearman
correlation analysis confirmed positive association between the
SPT6 knockdown-associated transcriptional changes and the
transcriptional program of GSCs in SUVA data set (Fig. 2h,
Supplementary Fig. 2e and Supplementary Data 5; false discovery
rate, FDR < 0.05; rs: −0.281, p-value < 2.2e−16).
SPT6 silencing induces DDR, cell cycle arrest, and apoptosis.
Activation of the DDR coordinates the inherent response of cells
to DNA damage, in which ATM and ATR kinases monitor
genome integrity to activate the DDR29. Activated ATM leads to
phosphorylation of γH2AX, and the activation of mediators and
adaptor proteins, such as 53BP1 and BRCA114,30. Immunoblot
analysis to investigate the effects of SPT6 silencing on the DDR
revealed increased phosphorylation of ATM. ATM activates the
cell-cycle checkpoints or induces apoptosis by phosphorylating
itself and the effector kinase CHK2, which in turn activates the
tumor suppressor p53 through Ser15 phosphorylation31.
SPT6 silencing induced the activating phosphorylation of CHK2
at Thr68 and p53 at Ser15, thus confirming DDR activation
(Fig. 3a). Next, we examined the cell cycle kinetics in GSCs
transfected with siCON and siSPT6. As shown in Fig. 3b, c (and
Supplementary Fig. 3a–b), SPT6 knockdown decreased both the
proliferative (the percentage of Ethynyl deoxyUridine positive S
phase cells) and mitotic (the percentage of H3Ser10 positive
mitotic cells) indexes and arrested GSCs at G2 phase. Aligned
with the impaired DNA repair capacity and DSB accumulation,
SPT6 knockdown markedly increased the number of polyploid
cells and the level of apoptosis (assessed by FACS analysis of
Annexin V and cleaved caspase 3 stained GSCs; Fig. 3d–f and
Supplementary Fig. 3c–d).
The preferential DDR activation in GSCs is thought to be a
pre-requisite for their radio-resistance5. Thus, we sought to test
the significance of SPT6 in the IR-induced DNA damage repair
capacity of radio-resistant GSCs. Quantification of IR-induced
γH2AX foci as well as measuring the tail moments with a comet
assay, confirmed significantly delayed DSB repair kinetics of
GSCs with silenced SPT6 compared to siCON (Fig. 3g, h and
Supplementary Fig. 3e–f). Collectively, these data suggest that
SPT6 is essential for DSBs repair, cell cycle progression and
contributes to radiation resistance in GBM.
SPT6 regulates the transcription of HR repair genes. In
immunofluorescence staining, SPT6 did not co-localize with
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Fig. 1 High-throughput siRNA screen identifies SPT6 as a regulator of genomic stability in glioblastoma stem-like cells. a DSBs quantification using a
comet assay in matched GSCs and DGCs isolated from GBM01 and GBM02 GBM lines. Data are presented as mean values ± s.d. ****p < 0.0001 (GBM01),
***p= 0.0003 (GBM02); two-tailed unpaired t-test. The right part of the panel is showing representative images of comets captured using 10x objective.
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positive control (BRCA1) are indicated. The top-scoring hit, SPT6, is highlighted as a green dot. d γH2AX mean intensity quantification in matched GSCs
and DGCs (GBM01 and GBM02) transfected with siCON or a pool of three independent siRNAs (siSPT6-p). Data are presented as mean values ± s.e.m.
***p= 0.0004 (GBM01-GSCs), non-significant ns= 0.637 (GM01-DGCs), *p= 0.022 (GBM02-GSCs), non-significant ns= 0.631 (GBM02-DGCs); two-
tailed unpaired t-test. e, f Representative confocal microscopy images of γH2AX staining (green foci) in SPT6 silenced (siSPT6-p) GSCs (e) and DGCs (f)
compared to respective control (siCON). Nuclei were counterstained with DAPI (blue). Images were captured using ×40 objective. Scale bar= 5 μm. N= 3
biologically independent experiments in (a), (d), (e), (f). Source data are provided as a Source data file.
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γH2AX foci (Supplementary Fig. 4a), implying that its impact on
DNA repair may be indirect. The role of SPT6 as a transcription
elongation factor prompted us to speculate that SPT6 executes its
role in DSB repair by modulating the transcription of RNA
polymerase II (RNAP II)-transcribed genes, in general, and DNA
repair genes, in particular. First, we assessed the impact of SPT6
loss on RNAP II protein levels and global transcription rates
(assessed by pulse-labeling of nascent RNA with Ethynyl Uridine;
EU followed by FACS). Global transcription rates declined by
more than 50% upon SPT6 downregulation (Fig. 4a and Sup-
plementary Fig. 4b), a phenomenon associated with a marked
decrease in RNAP II and H3K36me3 levels (Fig. 4b and Sup-
plementary Fig. 4c). Cycloheximide (CHX) chase assay showed a
significantly decreased half-life of RNAP II in cells with silenced
SPT6 (Fig. 4c). When treated with proteasomal inhibitor MG132
(20 µM, 5 h), RNAP II protein levels in GSCs transfected with
siRNA targeting SPT6 increased (Fig. 4d). Overall, these data
suggest that in GSCs, SPT6 binding to RNAP II prevents its
ubiquitin-mediated proteasomal degradation and thereby main-
tains the global transcription rates.
To gain deeper insight into the mechanism(s) contributing to
the SPT6-mediated DNA repair and cell proliferation, we
leveraged the SPT6 data set and searched for genes the
transcription of which was significantly altered as a result of
SPT6 loss. As represented by Bland-Altman (MA plot) plot,
4966 genes were significantly upregulated and 4969 genes were
downregulated in GSCs with silenced SPT6 (FDR < 0.05; Fig. 4e
and Supplementary Data 3 and 4). An unbiased clustering
analysis identified SPT6 as a regulator of RNA metabolism, cell
survival, proliferation and carcinogenesis (Fig. 4f and Supple-
mentary Data 6). Gene Set Enrichment Analysis (GSEA)
indicated that DNA repair transcriptional programs were
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downregulated in GSCs with SPT6 knockdown (FDR < 0.05;
Supplementary Fig. 4d and Supplementary Data 4), an
observation mirroring the impaired capacity of GSCs to repair
DSBs upon SPT6 loss. BRCA1 and RAD51 (p= 2.6e−07 and
p= 1.8e−03, respectively), two factors essential for DSBs repair
via error-free HR repair (further denoted as ‘HR genes’) were
among significantly downregulated DNA repair genes in SPT6
data set. A validation experiment using qRT-PCR confirmed
that the SPT6 knockdown-associated reduction in BRCA1 and
RAD51 levels is unique to GSCs (Fig. 4g, h and Supplementary
Fig. 4e). Consistent with a decrease in mRNA expression,
immunoblot analysis confirmed lowered BRCA1 and RAD51
protein levels in GSCs with silenced SPT6 (Fig. 4i and
Supplementary Fig. 4c).
SPT6 knockdown-mediated decline in RNAP II protein and
global transcription (see above), could contribute to such a
decrease in BRCA1/RAD51 expression. Thus, we examined the
correlation between transcriptional changes observed upon SPT6
knockdown and previously reported half-life of human coding
mRNAs32. This analysis confirmed that our results are not biased
by the global decrease in transcription and RNAP II protein levels
(Supplementary Fig. 4f).
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or SPT6-p (GBM01 and GBM02). Data are presented as mean values ± s.d. ***p= 0.006 (GBM01), ***p= 0.0003 (GBM02). d FACS analysis of polyploid
cells fraction (%) in GSCs transfected with siCON or siSPT6-p. Data are presented as mean values ± s.d. **p= 0.0013 (GBM01), **p= 0.0062 (GBM02).
e FACS-based quantification of Annexin V-positive (%) GSCs after transfection with siCON or siSPT6-p. Data are presented as mean values ± s.d. ***p=
0.0002 (GBM01), ***p < 0.0001 (GBM02). f FACS analysis of cleaved caspase-3-positive GSCs after transfection with siCON or siSPT6-p. Data are
presented as mean values ± s.d. ***p= 0.0018 (GBM01), **p= 0.0011 (GBM02). g γH2AX foci quantification at 0, 1 and 24 hrs after the exposure to
ionizing radiation (IR, 3 Gy) in GSCs transfected with siCON or siSPT6-p. Data are presented as mean ± s.d. ***p= 0.0007, *p= 0.0101. h Representative
DSBs quantification using comet assay (h) 0, 1, and 24 h after the exposure to ionizing radiation (IR, 3 Gy) in GSCs transfected with siCON or siSPT6-p.
Data are presented as mean ± s.d. ****p < 0.001. N= 3 biologically independent experiments in (a), (d–h), N= 4 biologically independent experiments in
(b) GBM01, N= 5 biologically independent experiments in (c) and N= 6 biologically independent experiments in (b) GBM02. Two-tailed unpaired t-test
used in (b–h). Source data are provided as a Source data file.
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While MG132 treatment restored RNAP II protein levels, both
mRNA and protein levels of BRCA1 and RAD51 remained lower
in GSCs with silenced SPT6 (Fig. 4d and Supplementary Fig. 4g),
implying that SPT6 is essential for RNAP II-mediated transcrip-
tion of BRCA1 and RAD51. To validate that SPT6 acts as a
transcriptional co-activator of BRCA1 expression in GSCs, we
performed a ChIP-qPCR assay. As shown in Fig. 4j, this assay
confirmed SPT6 binding to distal regulatory region of BRCA1
gene promoter.
SPT6 dictates DSB repair pathway choice. To evaluate the
extent of HR suppression after SPT6/BRCA1 loss, we employed
the well-established DR-GFP assay using U2OS cells (a bench-
mark cell line widely used in DNA repair field to measure HR
activity). SPT6 knockdown in U2OS cells reproduced the DNA
repair phenotype observed in GSCs (Supplementary Fig. 5).
siRNAs targeting SPT6 resulted in HR suppression similar in
magnitude to that seen with siRNAs targeting the key HR protein
BRCA1 (Fig. 5a). BRCA1 was reported to antagonize 53BP1-
dependent DNA repair in S/G2 phase by inhibiting its interaction
with chromatin proximal to DSB33. The activation of error-prone
repair of DSBs by NHEJ (here referred to as de-regulated NHEJ;
dNHEJ) increases the frequency of deleterious mutagenic events34
and is more prevalent in polyploid cancer cells35. Besides a sig-
nificant increase in NHEJ (Fig. 5b), SPT6 knockdown increased
the frequency of dNHEJ (evaluated by scoring 53BP1 foci count
in S/G2 cells) as well as the number of polyploid cells (Fig. 5c, d).
Similar to SPT6, HR genes were preferentially expressed by
GSCs and their expression decreased during serum-induced
differentiation. 53BP1 expression (NHEJ) followed the opposite
trend, with both the total protein levels as well as foci count
increased in DGCs (Fig. 5e–g). To examine the impact of
differential BRCA1 and 53BP1 expression on the DSBs repair
pathway choice in the context of cellular hierarchies, we have
50
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interrogated HR and NHEJ by scoring the BRCA1/53BP1 foci
formation and conducted DR-GFP/pEGFP-N3 plasmid-based
assay in a matched pair of GSCs and DGCs. This analyses
revealed that GSCs primarily utilize HR, which is concordant
with elevated BRCA1 recruitment in S/G2 phase cells (Fig. 5h).
Even though 53BP1 recruitment (foci count) was higher in G1
phase GSCs, the pEGFP-N3 plasmid-based repair assay con-
firmed higher NHEJ rates in DGCs (Fig. 5i). Given that DGCs
expressed much lower levels of BRCA1, we speculated that this is
due to the elevated 53BP1-dependent DNA repair in S/G2 phase
(dNHEJ). Indeed, microscopy-based analysis of 53BP1 foci count
(in the context of cell cycle) revealed that dNHEJ rate in DGCs is
markedly increased compared to that of GSCs (Fig. 5j), and
associates with a significant increase in the frequency of polyploid
cells (Fig. 5k). Importantly, SPT6 knockdown reduced BRCA1
expression and HR activity in GSCs, and shifted DSBs repair
towards dNHEJ (Fig. 5l, m and Supplementary Fig. 6a–c).
Altogether, these data indicate that the SPT6 high /BRCA1high-
expressing GSCs execute DSBs repair predominantly via HR to
maintain genomic stability, while SPT6 low /BRCA1low-expressing
DGCs rely on NHEJ/dNHEJ, which renders them more
susceptible to DSBs formation and genomic instability.
Ectopic BRCA1 expression rescues SPT6 loss phenotype. Stable
binding of 53BP1 to DNA ends channels DSB repair into NHEJ,
in part by suppressing end resection, a process that is necessary
for the generation of long stretches of single-stranded DNA
(ssDNA) needed for HR36,37. In the absence of BRCA1, 53BP1
has been shown to promote mutagenic NHEJ at replication-
associated DSBs, leading to gross chromosomal rearrange-
ments14. To understand whether BRCA1 loss is responsible for
g
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the activation of dNHEJ, and whether its ectopic expression
rescues the SPT6-BRCA1 loss phenotype, we stably overexpressed
BRCA1 (BRCA1-GFP) in U2OS cells (Fig. 6a). BRCA1-GFP cells
and cells transfected with backbone control (GFP) were then
transfected with either siCON or siSPT6. The introduction of
ectopic BRCA1 rescued the activation of DDR (assessed by
immunoblot analysis of ATM Ser1981 phosphorylation) upon
SPT6 silencing (Fig. 6a) as well as DSB induction as assessed by
γH2AX foci count and comet assay (Fig. 6b, c). Importantly, re-
introduction of BRCA1 prevented 53BP1 recruitment to DSBs in
S/G2 and restricted 53BP1 foci formation to G1 cell cycle phase
(Fig. 6d).
Chaetocin as a drug candidate mimicking ‘SPT6 LOSS’. One of
the first criteria to consider SPT6 a putative therapeutic target,
SPT6 expression would be expected higher in gliomas compared
to that of normal brain (NB) to rule out potential side effects of its
targeting in healthy tissue. Indeed, immunohistochemistry (IHC)
analysis revealed that the expression of SPT6 is elevated in GBM
(n= 24) compared to non-malignant brain control (NB; n= 10)
(Fig. 7a and Supplementary Fig. 7a). Immunoblot analysis con-
firmed higher expression of SPT6 in protein extracts from pri-
mary GBM patient-derived GSCs (GBM01-03) compared to
normal human astrocytes (NHA33; NHA59) and whole-brain
lysate (WBL; Supplementary Fig. 7b).
In silico analysis of the REMBRANDT data set showed that
SPT6 expression is significantly increased in malignant gliomas
compared to NB and that this expression does not correlate with
WHO grade (Supplementary Fig. 7c–d). Kaplan–Meier survival
analysis confirmed a negative correlation between high SPT6
expression (SPT6high) and glioma (WHO grade II–IV) patient
survival (Supplementary Fig. 7e). When assessing the impact of
SPT6 expression on GBM (WHO grade IV) patient survival only
(REMBRANDT data set), SPT6low group exhibited longer
survival compared to that of SPT6high GBM patients (Supple-
mentary Fig. 7f). Additional analysis of Gravendeel, TCGA GBM
Array and TCGA GBM RNAseq data sets failed to validate these
findings, concluding no correlation between SPT6 expression and
GBM patient survival (Supplementary Fig. 7g).
Due to the lack of specific inhibitor of SPT6 on the market, we
leveraged an open resource CONNECTIVITY MAP (CMap)38
and matched the transcriptome profile of GSCs with silenced
SPT6 to data sets available in CMap (Fig. 7b and Supplementary
Data 7). This approach identified chaetocin, a non-specific
inhibitor of histone lysine methyltransferases, as our top
candidate mimicking SPT6 loss at a transcriptome level. As
shown in Fig. 7c–e and Supplementary Fig. 7g, chaetocin
treatment reduced both SPT6 and BRCA1 protein and mRNA
levels, induced DSBs and reduced cell proliferation. Importantly,
GSCs showed greater sensitivity to chaetocin than NHA (Fig. 7f),
thus opening a therapeutic window for SPT6 targeting in GBM.
Next, we evaluated the effect of chaetocin on tumor-initiating
capacity of GSCs. Strikingly, the treatment of GSCs with as little
as 30 nM of chaetocin completely abrogated their capacity to
initiate tumors in vivo (Supplementary Fig. 7h). To further
explore the therapeutic potential of chaetocin, we treated tumor-
bearing mice intraperitoneally with a vehicle control (DMSO) or
1 mg kg−1 of chaetocin triweekly over a period of two weeks (total
dose of 6 mg kg−1). As shown in Fig. 7g, chaetocin treatment
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significantly extended the survival of tumor-bearing mice by
11 days (p-value= 0.048).
Based on the data presented above, we propose a model
(Fig. 7h), in which SPT6 acts as transcriptional co-activator of
BRCA1 expression in GSCs. BRCA1 then directs DSBs repair
towards error-free repair by HR. Upon SPT6/BRCA1 loss, DNA
repair pathway choice is deregulated and allows for the activation
of dNHEJ, which increases the genomic instability of GSCs,
ultimately leading to cell death by apoptosis. Both in vitro and
in vivo studies using siRNA/shRNA targeting SPT6 and chaetocin
as a drug mimicking the SPT6 loss phenotype validate SPT6 as a
bona fide therapeutic target in GBM.
Discussion
To identify new determinants governing the preferential capacity
of GSCs for error-free DSBs repair, we performed a microscopy-
based high-throughput siRNA screen, which revealed vulner-
abilities specific to this therapeutically resistant sub-population of
GBM. Importantly, proteins such as WEE1, CHK1 and BRCA1
with already established role in DNA repair, ranked among the
top candidates. In response do DNA damage, WEE1 activates G2/
M checkpoint. Its inhibition in GBM cells abrogated the G2/M
arrest and propelled them to prematurely enter into mitosis and
consequent cell death through mitotic catastrophe and apopto-
sis39. CHK1 is a key DDR factor, the loss of which leads to G2
checkpoint abrogation and sensitizes GSCs to ionizing radiation
(IR)40. BRCA1 functions in a number of cellular pathways that
maintain genomic stability, including DNA damage-induced cell
cycle checkpoint activation, DNA repair, replication fork integ-
rity, chromatin remodeling, as well as transcriptional regulation
and apoptosis41. Recently, we have discovered a tumor-
promoting role of BRCA1 in GBM, in supporting tumor cell
fitness and growth through protection from endogenous repli-
cation stress via transcriptional upregulation of RRM29.
Here, we identify SPT6, a histone chaperone and transcription
elongation factor, to be essential for the DNA repair capacity and
maintenance of GSCs. SPT6 plays a key role in the regulation of
transcription initiation, elongation, and 3′ end formation24,25,42–44.
Mutation of SPT6 facilitates chromatin relaxation in specific
genomic regions, which impacts the regulation of transcription,
a
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0.0002 (GBM02); two-tailed unpaired t-test. f GI50 calculation CHAE treatment in GSCs (GBM01 and GBM02) and NHA33 cells. **p= 0.0017 (NHA33 vs
GBM01) and ***p= 0.0010 (NHA33 vs GBM02); one-way ANOVA followed by Dunnett’s multiple comparison test. g Kaplan–Meier survival curves for
mice implanted with GBM01 GSCs and treated intraperitoneally with either vehicle (DMSO) or chaetocin (n= 5 mice per group) three times a week for a
period of two weeks. MS=Median Survival. Statistical significance was tested using Log-rank/Mantel-Cox test; *p= 0.048. h Model depicting the
mechanistic role of SPT6 in the regulation of DSB repair pathway choice via the transcriptional regulation of BRCA1. N= 3 biologically independent
experiments in (c–f). Source data are provided as a Source data file.
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genomic stability and hyperrecombination23,43–48. Previous reports
implicated SPT6’s chromatin remodeling activities to regulate zeb-
rafish myogenesis49 and mouse embryogenesis50. Here, we describe
a pro-tumorigenic role for SPT6 in GBM and provide a mechanistic
insight into its role in one of the deadliest of solid cancers. We find
SPT6 overexpressed in GBM when compared to non-malignant
brain controls (Fig. 7a). In silico analysis of REMBRANDT data set
confirmed increased SPT6 expression in malignant gliomas (com-
pared to NB) to be negatively correlated with patients’ survival
(Supplementary Fig. 7e–f). However, when assessing the impact of
SPT6 expression on the survival of GBM patients using additional
data sets (Gravendeel, TCGA GBM array and TCGA GBM RNA-
seq, Supplementary Fig. 7g), we found no association between SPT6
expression and GBM patient survival, implying that the prognostic
value of SPT6 is not independent of other variables such as
WHO grade.
Spt6 depletion in mouse ESCs decreases expression of plur-
ipotency transcription factors (TFs) and increases transcription of
cell-lineage-affiliated master TFs, leading to morphological
changes indicative of early cell differentiation45. Our data now
show that GSCs preferentially express SPT6, which is not only
essential for their maintenance and differentiation capacity, but
also tumorigenicity in vivo (Fig. 2).
The integrity of the human genome is constantly endangered
by a wide range of spontaneously occurring DNA lesions. BRCA1
and 53BP1 play a crucial role in regulating the DSB repair
pathway choice throughout the cell cycle, channeling DSBs repair
into either HR (S/G2 phase) or NHEJ (mainly G1 phase). Loss of
BRCA1 was found to cause a shift towards the mutagenic NHEJ
thereby inducing genomic instability, tumorigenesis, and
embryonic lethality16,36. Proper DNA repair pathway choice is
thereby paramount to cell survival, as the aberrant engagement of
the NHEJ pathway following replication fork collapse leads to
gross chromosomal rearrangements and cell death51. In 2006, Bao
et al. reported that GSCs, which preferentially activate DDR,
represent the radio-resistant sub-population in GBM tumor bulk.
GSCs, in contrast to DGCs, exhibit superior survival by evading
IR-induced apoptosis. Our findings show that at baseline, GSCs
have fewer unrepaired DSBs, which can be attributed to their
superior efficiency at executing DSB repair via both HR and
NHEJ (Figs. 1a and 5h, i). In our model, the high SPT6-regulated
BRCA1 expression in GSCs limits the recruitment of 53BP1 to
DSBs in S/G2 phase cells and thus prevents dNHEJ (Fig. 7h). In
contrast to GSCs, the expression of SPT6/BRCA1 in DGCs is low,
thereby enabling aberrant recruitment of 53BP1 in S/G2 cells and
activating error-prone DSB repair via NHEJ (dNHEJ) which
associates with increased polyploidy (Fig. 5j, k). Interestingly,
polyploidy has been associated with NHEJ as a primary mode of
DSBs repair, where Zheng et al.35 measured a twenty-fold
increase in NHEJ activity in the nuclear extracts from near-
polyploid aneuploid cells compared to those prepared from
diploid cells. Chromosomal instability and ploidy degree affect
the tumorigenicity of GSCs52. Our data directly compare the
ploidy of matched GSCs and DGCs (Fig. 5k), and imply that the
baseline differences in the percentage of polyploid cells may be a
consequence of differential DSBs repair pathway choice in these
two sub-populations.
The interaction of SPT6 with RNAP II is important for com-
plete recruitment of the SPT6/RNAP II complex across genes and
thus for a proper mRNA turnover23. SPT6 is essential for the
phosphorylation of C-terminal domain of RNAP II (CTD) at Ser2
and that mutation in the CTD results in loss of SPT6 protein
stability24.
We show that SPT6 loss leads to proteasomal degradation of
RNAP II which in turn reduces global transcription rates in
general, and the expression of BRCA1 (mRNA and protein), in
particular (Fig. 4). These results corroborate previous findings,
based on transcriptional profiling of SPT6 silenced HELA cells
followed by SPT6-ChIP analysis, that validate BRCA1 as a direct
transcriptional target of SPT653. Our study not only validates
their observation, but also provides a mechanistic insight into the
consequences of SPT6 knockdown-mediated BRCA1 down-
regulation on genomic stability in the context of cellular hier-
archies using unique GBM models. Another study has shown that
cell-cycle-associated transcripts are among the most highly sta-
bilized mRNAs in the absence of SPT6-RNAP II interaction,
causing severe cell cycle defects in the SPT6tSH2mutants23. This is
concordant with our results, where SPT6 loss led to a G1-S
transition defects and cell cycle arrest at G2 phase (Fig. 3b and
Supplementary Fig. 3a).
Elongator and Suppressor of Ty4 (SPT4)/SPT5 are transcrip-
tion elongation factors that contribute to the regulation of mRNA
synthesis by RNA polymerase II in the chromatin context. During
the process of immunoglobulin class switch recombination
(CSR), the interaction of transcription elongation factor SPT5
with activation-induced cytidine deaminase (AID) is crucial for
the recruitment of AID to its Ig and non-Ig targets54. SPT5
together with SPT4 were implicated in the regulation of both HR
and NHEJ26. SPT5 loss in zebra fish was associated with G1 cell
cycle arrest and transcriptional changes affected genes involved in
diverse biological pathways such as stress response and cell fate
specification, but not DNA repair55. In HELA cells, SPT5
knockdown induced expression changes that impacted RNA
metabolism, cell cycle leading to G1 arrest, senescence and sub-
sequently cell death by apoptosis56. Even though SPT6 is not the
only transcription elongation factor implicated in DNA repair, it
is the only one executing its function via transcriptional upre-
gulation of DNA repair genes.
By subjecting the SPT6 data set (Supplementary Data 3 and 7)
to CMap analysis, we identified a number of drugs mimicking
SPT6 loss phenotype. Number one on the list was idarubicin, as
chemotherapeutic agent and an anthracycline antileukemic drug,
which interferes with topoisomerase II and has already been
clinically tested as monotherapy in GBM57. The second-highest
scoring drug was a Polo-like Kinase (PLK) inhibitor BT-2536,
which has been tested in Phase II clinical trial in other solid
tumors58. The third candidate, which we chose for further vali-
dation, chaetocin, is a fungal mycotoxin known to cause unspe-
cific histone demethylation59. Chaetocin treatment of GSCs led
to: (i) decline in both SPT6 and BRCA1 protein levels; (ii)
induced DSBs; (iii) cell cycle arrest; and (iv) increased apoptosis,
thereby mimicking the SPT6 knockdown phenotype. The pre-
treatment of GSCs with chaetocin abrogated their tumor-
initiating capacity in vivo (Supplementary Fig. 7h) and most
importantly, chaetocin treatment of tumor-bearing mice sig-
nificantly extended their survival (Fig. 7g). These observations,
together with the previously reported ability of chaetocin to (i)
induce ROS in leukemia cells60; (ii) attenuate HIF1-activity and
thereby angiogenesis in hepatocellular carcinoma xenograft
models61; and trigger apoptosis in melanoma cells62; make
chaetocin an attractive alternative for therapeutic intervention in
therapeutically resistant GBM.
In this study, we describe an oncogene-like function for SPT6 in
GBM, one of the deadliest of solid cancers. Our data reveal that
SPT6 is essential for the maintenance and tumor-initiating potential
of GSCs as well as their capacity to repair endogenous and/or
irradiation-induced DNA damage. Moreover, our work has
unveiled a previously unknown mechanistic insight into the role of
SPT6 in DNA repair in the context of cellular hierarchies. The
genetic targeting of SPT6 by shRNA and the use of chaetocin as the
‘mimic’ for SPT6 loss in a pre-clinical orthotopic xenograft model
impaired the tumor growth in vivo and significantly improved the
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survival of tumor-bearing mice. In addition, our work describes the
regulatory mechanism by which SPT6 dictates the DSB repair
pathway choice via transcriptional upregulation of BRCA1, thereby
promoting the error-free HR and genomic stability of GSCs
(Fig. 7h). Collectively, our study sheds light on the functional
implication of SPT6 in tumorigenesis, providing sufficient evidence
for its role as a putative therapeutic target in GBM.
Methods
Primary GBM lines, xenograft passaging, and commercial lines. All cell models
were derived from tissue specimens obtained after surgery in patients diagnosed
with GBM. Primary GBM line T4121 (GBM01) was acquired from J.N Rich
(University of California, San Diego, CA, USA) Rich lab, in accordance with Ohio
State University or Cleveland Clinic Institutional Review Board. GBM02 and
GBM03 were established from freshly resected tumor tissue including informed
consent from each patient, as outlined by the Regional Danish Ethical Committee/
Danish Data Protection Agency (H-3-2009-136_63114). GBM lines were passaged
as xenografts in the subcutaneous flank of NOG mice (Taconic, TAC:nog)
according to Danish Welfare Law on Animal Experiments Act no 1306, protocol:
2012-15-2934-00636.
All GBM lines were authenticated to be unique by ATCC STR profiling and
routinely tested for mycoplasma.
U2OS and HEK293T cells were purchased from ATCC and maintained as
adherent cultures in DMEM with 10% FBS. U2OS-BRCA1-GFP cells were a gift
from J. Bartek (Danish Cancer Society, Denmark). U2OS DR-GFP and U2OS EJ5-
GFP cells were a gift from Dr. Pablo Huertas (University of Seville, Spain)63.
Normal Human Astrocytes-Hippocampal (NHA33 and NHA59) were purchased
from 3H biomedical (SC1830, 3H Biomedical) and maintained at low passages
(max passage 7) in commercially available Complete Astrocyte medium (SC1801,
3H Biomedical) according to manufacturer instructions. All cells were cultured at
37 °C in an atmosphere of 95% air and 5% CO2.
In vivo patient-derived GBM studies. All intracranial studies were carried out
according to Danish Welfare Law on Animal Experiments Act no 1306, protocol:
2012-15-2934-00636. For in vivo survival studies, a total of 5 × 104 live cells
transduced with either SPT6 shRNA or shLuciferase (shLuc) were stereotactically
implanted into right frontal lobe of wild type, female Balb/c nu/nu mice (5 mice/
group, 8 weeks). For chaetocin (CHAE, Selleckchem S8068) studies: (A) tumor
initiation study: 1 × 104 GBM01 GCSs CHAE-pretreated cells (30 nM; 24 h) were
stereotactically implanted into right frontal lobe of 6 weeks old female NMRInu/nu
mice (seven mice per arm); (B) therapeutic efficacy study: 1 × 104 GBM01 GCSs
were stereotactically implanted into the right frontal lobe of 6-week-old female
NMRInu/nu mice (five mice per arm) and randomized into two groups. At day 3
post-implantation, mice were intraperitoneally treated with vehicle control
(DMSO) or 1 mg kg−1 chaetocin three times a week for a period of 2 weeks (total
dose of 6 mg kg−1). All mice were kept in the same conditions, with access to food
and water ad libitum in a 12-h light/dark cycle. Mice were monitored and sacrificed
by an animal caretaker blinded to study design at the onset of neurological
impairment, loss of balance and appetite, hunching, weight loss. Mice that
remained asymptomatic were sacrificed at the end of respective study (85 days
post-implantation for SPT6 shRNA study in Fig. 2f, and chaetocin treatment study
in Fig. 7g; 105 days post-implantation for chaetocin pre-treatment study (Sup-
plementary Fig. 7h).
Tumor dissociation and GBM cell culture. Freshly resected xenografts were
dissected and mechanically dissociated according to the Papain Dissociation pro-
tocol (Worthington Biochemical Corporation, New Jersey, cat.no.LK003150).
Isolated cells from xenografts were maintained as suspension cultures in complete
media containing Neurobasal –A medium (12349-015, Invitrogen), supplemented
with B27 minus Vitamin A (12587-010, Invitrogen), EGF (20 ng ml−1) (236-EG-
01M, R&D systems), FGF (20 ng ml−1) (4114-TC-01M, R&D systems), GlutaMax
(35050-038, Invitrogen) and antibiotics (15140-122, Invitrogen). Cells were allowed
to recover for 24 h prior their use in downstream experiments. Matched GBM
cancer-stem like cells (GSCs, CD133+) and differentiated GBM cells (DGCs,
CD133−) populations were isolated by magnetic (MACS) sorting using CD133
microbeads kit (130-100-857, Miltenyi Biotec). The GSCs were maintained in
complete media, whilst the DGCs were maintained as monolayer in DMEM
(31966-021, Invitrogen), supplemented with 10% FBS (medium (15140-122,
Invitrogen) and antibiotics. Both populations were validated functionally by
sphere-forming capacity (ELDA) and expression of stem cell markers by immu-
noblotting for expression of SOX2 and GFAP.
siRNA screen and analysis. A customized siRNA library consisting of 296 gene
targets with known role in chromatin remodeling, positive (INCENP9) and
negative controls (scrambled siRNA control), with three independent validated
siRNAs per gene (Supplementary Data 1) was purchased from Ambion. A pool of
three individual siRNAs for each gene, to a final concentration of 900 nM per well,
was used to transfect a total of 4 × 105 cells using a 384-well NucleofectorTM
System and P3 NucleofectorTM Solution (Lonza). After transfection, cells were
transferred to a GelTrex-coated (A1413201 ThermoFisher) 384-well imaging plate
(Nunc) in growth factor (EGF, bFGF) free Neurobasal-A medium. 72 h later, cells
were pulse-labeled (30 min) with 5-ethynyl uridine (EdU; A10044, Life Technol-
ogies), then fixed with 4% PFA, permeabilized with 0.25% triton x-100 in PBS and
incubated with anti-γH2AXSer139 antibody for 1 h at RT. The incubation with
secondary anti-mouse Alexa Flour 488 conjugated antibody (9669S, Cell Signaling)
was followed by EdU detection according to the manufacturer’s instructions
(A10044, Life Technologies). Nuclei were counterstained with 4,6-Diamidino-2-
Phenylindole (DAPI) (D9542-10MG, Sigma Aldrich). Acquisition and analysis
were carried out using Olympus Scan-R screening station equipped with Scan-R
analysis software (Olympus).
RNAi knockdown, plasmid transfection, and treatment. GBM cells were wet-
reverse transfected using either HiPerfect Transfection Reagent (301705, Qiagen)
or Dharmafect1 (T-2001-03, GE Healthcare) according to manufacturer’s
instructions. For each transfection, 2 × 105 cells were transfected with 50 nM of
either pooled (siSPT6-p) or individual SPT6 siRNA (Ambion 4392420-Pre-
designed siRNA: siRNA-34: S13634; siRNA-35: S13635; siRNA-36: S13636) or
20 nM silencer select negative control siRNA (siCON) (4390844, Thermo Fisher
Scientific). For U2OS cells, in a 6 cm dish setting 4 × 105 cells were transfected with
siCON (20 nM) or siSPT6 (30 nM) siRNA using Lipofectamine RNAiMax (13778-
075, Invitrogen). All analysis and downstream experiments were carried out 72-h
post-transfection unless stated otherwise. pEGFP-C1 (Clontech, Cat discontinued)
transfection in U2OS cells was carried out using DharmaFECT kb (T-2006-01,
Dharmacon) according to manufacturer’s instructions. U2OS-pEGFP-C1-BRCA1
cell line was a gift from Dr. Jiri Bartek (Danish Cancer Society). When indicated,
cells we exposed to IR (IR; 3 Gy) using YXLON smart (YXLON International A/S)
system and/or treated with indicated doses of chaetocin (stock solution 10 mM)
prior processing for downstream assays.
Lentiviral particle preparation. HEK293T cells were co-transfected with packa-
ging plasmids (pMD2.G and psPAX) and pLKO plasmids (encoding shRNAs
targeting SPT6: shSPT6-1: TRCN0000278911, shSPT6-2: TRCN0000278845) or pI-
SceI-BFP (gift from Dr. Pablo Huertas, University of Seville, Spain) vector using a
Calcium Phosphate transfection kit (631312, Clontech). Lentiviral particles were
concentrated using PEG-it Virus Precipitation Solution (SBI, LV810A-1) and
stored in aliquots at −80 for later use.
Clonogenic assay. For colony formation, U2OS cells transfected with either
siCON or siSPT6 were plated at a density of 2500 cells per well in a 6-well plate and
allowed to attach overnight. The following day, cells were irradiated at 3 Gy or
sham-irradiated and monitored for 6 days. For analysis, cells were fixed and stained
using 0.5% crystal violet(w/v) (C0775-25G, Sigma Aldrich), scanned. Colonies were
quantified using Celigo Imaging Cytometer (Nexcelom Bioscience).
Flow cytometry. Apoptosis: In brief, single cells were incubated with Annexin V-
FITC (Dead cell apoptosis kit; V13242, BD bioscience) and processed according to
the manufacturer’s instructions. For Cleaved Caspase 3 staining, single cells were
fixed in 4% PFA, permeabilized, stained at 37 °C for 90 min with antibody against
cleaved caspase 3 (Asp175) conjugated with Alexa Flour 488 (9669S, Cell Signal-
ing). Cell nuclei were counterstained with DAPI.
Polyploidy: Here, single cells were fixed in 4% PFA for 10 min then
permeabilized in 0.25% triton-X in PBS for 10 min. The DNA content was
visualized by incubating the fixed cells with DAPI staining solution (10 μg ml−1 in
0.1% triton-X in PBS) for 2 h before analysis.
Proliferative index or S phase (EdU+ cells): Cells were pulse-labeled with 10 µM
EdU probe for 30 min, fixed using 4% PFA for 15 min and stained using Click-iT
EdU imaging kit according to manufacturer’s instructions (A10044, Life
Technologies). Nuclei were counterstained using DAPI.
Mitotic index (MI): Single cells were collected, fixed with 4% PFA, then
incubated with phospho-histone H3 (Ser10) Alexa Flour 647 conjugated antibody
(Cell Signaling Cat#9716). Cell nuclei were counterstained with DAPI.
Global transcription rates: Cells were pulse-labeled with EU probe (1 mM) for
1 h and stained using the Click-it RNA Alexa Flour 488 kit (C10329, Life
Technologies) according to manufacturer’s instructions.
HR/NHEJ repair rates: Upon transfection with HR or NHEJ repair plasmids, 48
h later cells were trypsinized and single-cell population analyzed for the frequency
of GFP positive cells.
All flow cytometry samples were run on BD FACS Verse (BD Biosciences) and
analyzed using FlowJo software (BD). Information on gating strategy is provided in
Supplementary Fig. 9.
Immunofluorescence. For immunofluorescence staining, cells grown on GelTrex-
coated coverslips were fixed with 4% PFA, permeabilized using 0.25% Triton-X or
pre-extracted for 3 min using a mix of 4% PFA and CSK buffer (20mM NaCl, 5mM
MgCl2, 1 mM PIPES, 1mM EGTA, 100mM Sucrose and 0.2% Triton-X) in ratio 1:1,
prior fixation with 4% PFA, followed by blocking in 3% BSA. Cells were incubated
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with primary antibody: rabbit polyclonal anti-Cyclin A (H-432) (sc-751, Santa Cruz,
mouse monoclonal anti BRCA1(D-9) (sc6954, Santa Cruz), Rabbit polyclonal anti-
53BP1 (ab36823, Abcam), mouse monoclonal anti-H2AXSer139 (05-636, Millipore)
or rabbit polyclonal anti SPT6 (Ab32820, Abcam), at 4 °C overnight or 2 h at RT,
followed by incubation with appropriate AlexaFlour488 or AlexaFlour568 conjugated
secondary antibody (1:1000). Nuclei were counterstained with 4,6-Diamidino-2-
Phenylindole (DAPI) (D9542-10MG, Sigma Aldrich).
For the two-dimensional analyses of 53BP1 and BRCA1 foci counts in the
context of cell cycle phases, cells were either pulse-labeled with EdU followed by
staining with a Click-iT EdU imaging kit (C10337, Life Technologies) or just
stained with antibody against cyclin A (to mark S/G2 phase cells)9. Automated
imaging and analysis were performed using Olympus Scan-R screening station
equipped with Scan-R analysis software. Where matched GSCs and DGCs were
assessed. To correct for differential nuclear area/size in matched GSCs and DGCs,
the absolute foci count per cell nucleus was normalized to Nuclear Area (NA).
Confocal images were acquired using Zeiss LSM800 confocal microscope.
Cell viability and GI50 calculation. For cell viability was cells transfected with
siCON, siSPT6-p or individual siRNAs (siSPT6-34, siSPT6-35 or siSPT6-36) were
seeded at a density of 3000 cells per well in 100 μl of media in 96-well plates, all in
triplicates. Cell viability was measured at indicated time points using CellTiter-Glo
Luminescent Cell Viability Assay (G7571, Promega). For GI50 studies, single cells
were seeded at 3000 cells per well in 50 μl of media in 96-well plates. After 24 h,
chaetocin (increasing concentrations as indicated) was added to a final volume of
100 µl. After 72 h, viability was measured using CellTiter-Glo Luminescent Cell
Viability Assay (G7571, Promega).
Extreme limiting dilution assay (ELDA). Self-renewal of GSCs was assessed by
ELDA64. In brief, cells transfected with siCON, siSPT6-p or individual siRNAs
(siSPT6-34, siSPT6-35 or siSPT6-36) were seeded in 96 well plate at a density of
500, 250, 100, 50, 10, and 1 cells per well. After 14 days, the presence of neuro-
spheres in each well was noted and data analyzed using the ELDA software (http://
bioinf.wehi.edu.au/software/elda).
Immunoblot analysis. Protein extracts were prepared using whole lysis buffer
(WLB; 50 mM Tris –HCl, 10% Glycerol, 2% SDS and water) and protein con-
centrations determined by Pierce BCA Protein Assay (23227, Thermo Scientific).
Cell lysates (25–30 µg) were separated by electrophoresis on SDS-PAGE gels
(BioRad). Proteins were transferred onto nitrocellulose membranes and incubated
appropriate primary and species-specific secondary antibodies (see Supplementary
Table 1). Amersham ECL Prime Western Blotting Detection Reagent (RPN2232,
GE Healthcare) was used for detection using Image Lab software (BioRad).
Uncropped immunoblot images are provided in Supplementary Fig. 8.
Alkaline comet assay. Single cells were resuspended in 0.5% low melting agarose
(LMA) (A9045-10G, Sigma), spread quickly onto 1% Ultra-Pure normal melting
agarose (NMA) (16500500, Invitrogen) pre-coated glass slides. Slides were
immersed into lysis buffer (2.5 M NaCl, 100 mM EDTA and 10 mM Trizma base)
overnight at 4 °C. Slides were then washed in neutralization buffer (Trizma base,
PH= 7.5, calibrated with HCl) to quench lysis and run in an electrophoresis
chamber at 25 V, 300 mA for 25 mins in a cold room, dehydrated in 96% ethanol,
and mounted in TE buffer with SYBR Gold (S11494, Thermo Fisher Scientific).
Comets were imaged by a fluorescence microscope (Axiovert 200M, Carl Zeiss)
and comet tails scored using with Comet assay IV software.
Immunohistochemistry. Paraffin-embedded, neoplastic, tumor tissue (8 µm; n=
24) and non-malignant control brain (8 µm; n= 10) sections were obtained from
the Department of Clinical and Molecular Pathology, Palacky University and
University Hospital Olomouc upon acquisition of a valid consent per the
requirement of regional ethics committee and stained as described previously9. In
brief, following antigen retrieval, tissue sections were treated in 6% H2O2 to block
endogenous peroxidase activity, then stained with primary antibody against SPT6
(1:100; ab32820, Abcam). After 1-h incubation at room temperature (RT), sections
were washed, incubated with EnVision+ Dual Link System-HRP secondary anti-
body for 1 h, and immunoreactivity visualized using liquid DAB+ substrate-
chromogen system. Slides were washed, dehydrated through graded ethanol and
mounted. The nuclei were counterstained with hematoxylin. SPT6 positivity was
scored as negative (0), low (1), medium (2), and high (3).
DSB repair assays. Repair pathways (HR and NHEJ) were assessed using U2OS
cells bearing a single copy of the reporter constructs EJ5-GFP and DR-GFP (gifts
from Dr. Pablo Huertas, University of Seville) as described by63 with minor
modifications. U2OS cells were wet-reverse transfected with indicated siRNAs:
SPT-6 pool, BRCA1 (Thermo Fisher Silencer Select Pre-designed and validated
siRNA S458) and 53BP1 (Sequence Sense 5’->3’ GAU ACU UGG UCU UAC UGG
UUU TT) at 30 nM. After 24 h, single cells were seeded at 70% confluency on
coverslips and allowed to attach overnight and transduced with I-SceI-BFP
lentiviral particles. The following day, cells were washed and fixed 24 h later with
4% PFA and cells double-positive for GFP and BFP were counted.
Repair pathways (HR and NHEJ) in matched GSCs and DGCs were performed
according to Lim et al.65. Cells (5 × 105) were transiently transfected with respective
DNA repair substrate plasmids (linearized HindIII pEGFP-N3 for NHEJ and DR-
GFP for HR) using DharmaFECT kb DNA transfection reagent. The DR-GFP
plasmid was co-transfected with a (1:2) I-Sce1 meganuclease expression plasmid
(pCMV-I-SceI). Transfection efficiencies were determined by co-transfection with
a circular pEGFP-N3 vector. Cells were analyzed 48 h post transfection by flow
cytometry (Becton Dickinson).
RNA extraction and real-time PCR. Total RNA was extracted using and RNeasy
Plus Mini Kit (QIAGEN-74134) according to the manufacturer’s instructions.
cDNA was synthesized from total RNA using the High Capacity cDNA reverse
transcription kit (Applied Biosystems). Real-time PCR was performed using FAST
SYBR Green Master mix (Applied Biosystems) according to the manufacturer’s
instructions. Amplification was performed in the Applied Biosystems 7500 Fast
Real-Time PCR System. Primer sequences are listed in Supplementary Table 2.
HPRT1 was used as house-keeping control and ΔΔCT method was used to cal-
culate fold change expression9.
ChIP qPCR. For chromatin immunoprecipitation 5 × 106 GSCs were plated and
recovered overnight, then crosslinked in 1% PFA in cell culture media for 10 mins
with gentle shaking. Glycine (125 mM) was added to mixture for 10 min at room
temperature (RT). Next, cells were washed twice in ice-cold PBS cold and pelleted
at 1400 rpm for 5 min. prior lysis43. The isolated chromatin fraction was frag-
mentized using the Covaris M220 (27 min; peak power: 75; duty factor: 10; cycles/
burst: 200). Soluble chromatin fraction was isolated by centrifugation at 13,000 rpm
at 4 °C for 10 min. For immunoprecipitation, Protein Dynabeads G were washed
and incubated for 6 h with IgG, at 4 °C on a rotating wheel. The chromatin was
precleared by incubation with a mixture of beads and IgG for 30 mins at RT in
rotation. 10% of the precleared chromatin was taken as input control. The pre-
cleared chromatin was diluted in dilution buffer (10 mM Tris-HCl pH8.0, 5 mM
EDTA, 0.5% Triton X-100 and 0.15M NaCl) and incubated with ChIP-grade
antibody targeting either IgG control- or SPT6 (NB100-2582, Novus Biologicals)—
coupled beads overnight at 4 °C on a rotating wheel. Washing was performed using
1 mL of buffer A (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 0.05% SDS, 1% Triton X-
100 and 0.165 M NaCl) followed by a wash with 1 mL of buffer B (20 mM Tris-HCl
pH8.0, 2 mM EDTA, 0.05% SDS, 1% Triton X-100 and 0.5 M NaCl), 1 mL of buffer
C (10 mM Tris-HCl pH8.0, 1 mM EDTA, 1% NP-40, 1% Sodium Deoxycholate
and 0.25 M LiCl) and then twice in 1 mL of buffer D (10 mM Tris-HCl pH8.0 and
1 mM EDTA). All washes were performed at 4 °C. Immunoprecipitated chromatin
and total input control were decross-linked using 0.01 mgmL−1 RNase A in 300
mL of buffer E (1% SDS, 0.1 M NaHCO3 and 0.5 M NaCl) at 65 °C for at least 4 h
which gentle shaking at 750 rpm. Next, 30 μL of 10× Proteinase K buffer (200 mM
Tris-HCl pH 6.5, 150 mM EDTA and Proteinase K 0.3 mgmL−1) was added and
samples were then incubated 45 °C for 2 hrs. The DNA fragments were purified
using phenol/chloroform (pH 7.0) and ethanol precipitation. Eluted DNA was used
as a template for qPCR analysis using Applied Biosystems 7500 Fast Real-Time
PCR Systems. BRCA1 primers (Supplementary Table 2) were designed based on
the human BRCA1 distal promoter.
In silico analyses of public data sets. The pre-processed CPM normalized data
from Suva data set28 was downloaded from GEO (GSE54791). The CPM matrix
was log2 transformed with a pseudo-count of 1 and re-analyzed for differential
gene expression (GSCs vs DGCs, called ‘TPC’ and ‘DGC’ by Suva et al.) using a
standard limma DE workflow with minor modification to account for the non-
independence of the replicates from the same patient-derived model66. The black
trend line is calculated as a smoothed average along the x-axis where the shaded
region indicates standard error. Results are summarized in Supplementary Data 5.
The differential SPT6 mRNA expression in NB in comparison to malignant glio-
mas and its impact on patient survival was assessed using indicated data sets via
http://gliovis.bioinfo.cnio.es/67.
RNA sequencing and analysis. Total RNA isolated from GBM01 GSCs trans-
fected with either siCON or siSPT6-p using RNeasy Plus Mini kit (QIAGEN
#74134) was subjected to a library preparation and pair-end sequencing using BGI
services (https://www.bgi.com).
Trimming and mapping: The following analysis service was provided by GATC
Biotech: Reads were timed using Trimmomatic v0.33 and were mapped to hg19
with TopHat 2.0.14 guided by Gencode v19.
Quantification and filtering: Gencode v19 Gene expression was quantified via
featureCount only counting reads mapping uniquely to individual gene. Inter
library normalization was done using with edgeR 3.14.0 using the ‘TMM’ method.
Only genes expressed more than 1 RPKM in at least three samples were kept for
subsequent analysis (n= 13,693).
Differential gene expression: Genes were tested for differential expression using
edgeR’s glmLRT function with a design accounting for the paired nature of the
independent experiments (Supplementary Data 3). P-values were corrected for
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multiple testing using the Benjamini-Hochberg approach. An FDR value < 0.05 was
considered significant.
Gene set overrepresentation analysis (OA): Gene set annotation was obtained
from Gene Ontology68 and MSigDB v5 (http://bioinf.wehi.edu.au/software/
MSigDB/) and only the sets H (Hallmark sets), C2 (Curated sets) and C6
(Oncogenic signature sets) were used. Gene Ontology gene set were downloaded
from EBI’s official mirror January 2016 and to avoid the bulk of gene-duplication
only gene sets at level 6 of the biological process hierarchical ontology structure was
used (referred to as the GO gene set). Ensemble IDs were translated to gene-names
using biomaRt. Overrepresentation was done via R’s fishers.exact() test with
alternative= greater (Supplementary Data 4). P-values were corrected for multiple
testing using the Benjamini-Hochberg approach (FDR). An FDR value < 0.05 was
considered significant.
Clustering of gene set overrepresentation: Up- and downregulated results were
clustered separately and only gene sets significantly overrepresented (FDR < 0.01)
was used for the clustering. To cluster gene sets a graph connecting all gene sets to
all gene sets was constructed. The score of each connection was measured as the
Jaccard similarity (the fraction of genes in the union of the two gene sets which
were found in both). The graph was trimmed by only keeping connections with a
Jaccard similarity >= 0.15 and with at least 5 genes in the overlap. The Louvain
method (implemented in the igraph R package) was used to identify clusters of
overlapping gene sets. We derived the title of each cluster via the natural language
processing tools implemented in the R package tidytext. For each gene set we
separated the gene set name into its distinct words. The words: reactome, kegg, dn,
up, network, corr; were added to the list of common stop-words (which were
removed) and the text mining statistics tf-idf was calculated for each word in each
cluster. In the context of gene set clusters the tf-idf statistics is a convenient way of
identifying the words which best described one gene set cluster compared to the
words of gene sets from all other clusters, while at the same time taking the word
frequency into account (for details see https://www.tidytextmining.com/tfidf.html).
For each cluster we extracted the top 10 words with the highest tf-idf score and
from those the cluster titles were manually constructed. Only clusters containing
gene sets from more than one source were annotated (else marked NA). To
improve the visual presentation 2 “unclear” unconnected clusters, as well as the
following 3 unconnected clusters, were removed from the visualization:
Aminoacytelation, Monosaccharide processes and ERBB2 and MEK signaling. The
entire process is documented in Supplementary Data 6.
Analysis of specific gene sets: DNA repair gene sets were extracted by selecting
all gene sets containing one of the following words: repair, homologous,
nonhomologous or non_homologous. Stem-cell gene sets were extracted by
selecting all gene sets containing stem_cell in its name and afterwards remove all
sets containing either of the following (sub)words in the description: hematopo,
mammary, leukemic or lymphoid. Afterwards the top 250 upregulated genes
(ranked by p-value) from the Suva data set was added as a stem-cell gene set.
Connectivity Map (CMap) analysis. We used The Connectivity Map (CMap)38 to
identify compounds mimicking transcriptional perturbation caused by SPT6
knockdown (Supplementary Data 7). Specifically, we extracted the top 500 most
up- and downregulated genes (sorted by p-value) after SPT6 silencing, converted
the gene_IDs to Entrez_IDs and uploaded them to the next generation CMap
server hosted at https://clue.io/.
Statistical analysis. The choice of sample size is similar to previously reported
studies9,11,69. GraphPad Prism 8 was used to assess statistical significance in every
case. For in vivo studies, Kaplan–Meier survival curves, log-rank test was per-
formed. For in vitro studies, statistical significance was assessed by two-tailed
unpaired Student’s t-test, or by one-way or two-way ANOVA followed by a post-
hoc analysis as indicated in the figure legends. For correlation analyses Spearman’s
rank correlation test was performed. Precise details on number of independent
experiments or samples and statistical tests can be found in the figure legends.
p values < 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw FASTQ files, as well as the gene count matrix have been submitted to NCBI’s
Gene Expression Omnibus (GEO) and have been assigned the accession number
GSE125621 and permanent URL: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE125621. The primary GBM cell lines can be shared with other investigators via
fully executed Material Transfer Agreement and Data Transfer Agreement approved by
the Danish Data Protection Agency. Uncropped images of individual immunoblot
membranes and FACS gating strategies are provided as a Supplementary Figs. 8 and 9.
Source Data are provided with this paper and contains key raw data presented in Figs. 1–
7 and in Supplementary Figs. 1–7. Antibodies and primers used in the study are listed in
Supplementary Tables 1 and 2. The data that support the findings in this study are
available within the Article, Supplementary Information or from the corresponding
author upon reasonable request. Source data are provided with this paper.
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